AU2013329464C1 - Proteolytic inactivation of select proteins in bacterial extracts for improved expression - Google Patents
Proteolytic inactivation of select proteins in bacterial extracts for improved expression Download PDFInfo
- Publication number
- AU2013329464C1 AU2013329464C1 AU2013329464A AU2013329464A AU2013329464C1 AU 2013329464 C1 AU2013329464 C1 AU 2013329464C1 AU 2013329464 A AU2013329464 A AU 2013329464A AU 2013329464 A AU2013329464 A AU 2013329464A AU 2013329464 C1 AU2013329464 C1 AU 2013329464C1
- Authority
- AU
- Australia
- Prior art keywords
- arg
- synthetic
- artificial sequence
- gly
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713245P | 2012-10-12 | 2012-10-12 | |
| US61/713,245 | 2012-10-12 | ||
| PCT/US2013/063804 WO2014058830A1 (en) | 2012-10-12 | 2013-10-08 | Proteolytic inactivation of select proteins in bacterial extracts for improved expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2013329464A1 AU2013329464A1 (en) | 2015-05-14 |
| AU2013329464B2 AU2013329464B2 (en) | 2017-07-27 |
| AU2013329464C1 true AU2013329464C1 (en) | 2018-02-15 |
Family
ID=49447839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013329464A Active AU2013329464C1 (en) | 2012-10-12 | 2013-10-08 | Proteolytic inactivation of select proteins in bacterial extracts for improved expression |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9650621B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2906592B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6421122B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102018863B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104837863B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013329464C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2887355C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2906592T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2694683T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE041721T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL238095B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2906592T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201502875VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014058830A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201502875VA (en) | 2012-10-12 | 2015-06-29 | Sutro Biopharma Inc | Proteolytic inactivation of select proteins in bacterial extracts for improved expression |
| WO2014172631A2 (en) * | 2013-04-19 | 2014-10-23 | Sutro Biopharma, Inc. | Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression |
| US10316322B2 (en) * | 2014-07-02 | 2019-06-11 | Sutro Biopharma, Inc. | High growth capacity auxotrophic Escherichia coli and methods of use |
| CN108779446B (zh) * | 2016-01-13 | 2023-04-21 | 新英格兰生物实验室公司 | T7 rna聚合酶的热稳定变体 |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| CN106801047A (zh) * | 2016-12-30 | 2017-06-06 | 武汉金开瑞生物工程有限公司 | 一种通过无细胞蛋白合成系统制备半胱氨酸蛋白酶的方法 |
| KR20190103256A (ko) | 2016-12-30 | 2019-09-04 | 수트로박스, 인코포레이티드 | 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체 |
| TW202426655A (zh) | 2017-07-11 | 2024-07-01 | 美商新索思股份有限公司 | 非天然核苷酸之導入及其方法 |
| BR112020002272A2 (pt) | 2017-08-03 | 2020-07-28 | Synthorx, Inc. | conjugados de citocina para o tratamento de doenças autoimunes |
| EA202090908A1 (ru) | 2017-10-12 | 2020-10-29 | Ваксайт, Инк. | Вакцина и связанные композиции для лечения пародонтита и способ применения |
| BR112020017016A2 (pt) | 2018-02-26 | 2020-12-29 | Synthorx, Inc. | Conjugados da il-15 e usos dos mesmos |
| JP7340591B2 (ja) * | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| CN108949796A (zh) * | 2018-07-27 | 2018-12-07 | 张家港市华天药业有限公司 | 一种用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法 |
| CN109055291A (zh) * | 2018-07-31 | 2018-12-21 | 张家港市华天药业有限公司 | 用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法 |
| BR112021005401A2 (pt) | 2018-11-08 | 2021-06-29 | Synthorx, Inc. | conjugados de interleucina 10 e usos dos mesmos |
| MA54952A (fr) | 2019-02-06 | 2022-05-11 | Synthorx Inc | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
| BR112021019826A2 (pt) | 2019-04-02 | 2021-12-07 | Vaxcyte Inc | Síntese otimizada de antígeno de plasmídeo de invasão b livre de célula e composições e métodos de uso relacionados |
| TWI873169B (zh) | 2019-08-15 | 2025-02-21 | 美商欣爍克斯公司 | 使用il-2接合物之免疫腫瘤學組合療法 |
| CN114746122A (zh) | 2019-09-10 | 2022-07-12 | 新索思股份有限公司 | Il-2缀合物和治疗自身免疫性疾病的使用方法 |
| IL291786A (en) | 2019-11-04 | 2022-06-01 | Synthorx Inc | Interleukin 10 conjugates and their use |
| US12351850B2 (en) * | 2020-04-30 | 2025-07-08 | Sutro Biopharma, Inc. | Methods of producing full-length antibodies using E. coli |
| IL299074A (en) | 2020-06-25 | 2023-02-01 | Synthorx Inc | Immuno-oncology therapeutic combination with IL-2 and anti-AGFR antibody conjugates |
| EP4211156A1 (en) * | 2020-09-14 | 2023-07-19 | Sutro Biopharma, Inc. | Method for large scale production of antibodies using a cell-free protein synthesis system |
| BR112023006364A2 (pt) | 2020-10-09 | 2023-05-09 | Synthorx Inc | Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe |
| EP4225375A1 (en) | 2020-10-09 | 2023-08-16 | Synthorx, Inc. | Immuno oncology therapies with il-2 conjugates |
| WO2022174102A1 (en) | 2021-02-12 | 2022-08-18 | Synthorx, Inc. | Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof |
| TW202245843A (zh) | 2021-02-12 | 2022-12-01 | 美商欣爍克斯公司 | Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法 |
| CN113322267B (zh) * | 2021-03-15 | 2024-01-05 | 天津大学 | 系统在提高非天然氨基酸的插入效率中的应用 |
| TW202313679A (zh) | 2021-06-03 | 2023-04-01 | 美商欣爍克斯公司 | 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法 |
| WO2023122573A1 (en) | 2021-12-20 | 2023-06-29 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
| WO2023122750A1 (en) | 2021-12-23 | 2023-06-29 | Synthorx, Inc. | Cancer combination therapy with il-2 conjugates and cetuximab |
| WO2024136899A1 (en) | 2022-12-21 | 2024-06-27 | Synthorx, Inc. | Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies |
| TW202444349A (zh) | 2023-03-20 | 2024-11-16 | 美商欣爍克斯公司 | 使用ｉｌ－２綴合物之癌症療法 |
| WO2025015041A1 (en) * | 2023-07-12 | 2025-01-16 | University Of Washington | Rna-only, positive control target for clinical diagnostic testing |
| WO2025158385A1 (en) | 2024-01-25 | 2025-07-31 | Genzyme Corporation | Pegylated il-2 for suppressing adaptive immune response to gene therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60040771D1 (de) * | 1999-03-04 | 2008-12-24 | Asubio Pharma Co Ltd | Verfahren zur kontrolle der spaltung mit ompt protease |
| WO2002059293A2 (en) | 2001-01-25 | 2002-08-01 | Forster Anthony C | Process and compositions for peptide, protein and peptidomimetic synthesis |
| WO2004016778A1 (en) | 2002-08-19 | 2004-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Improved methods of in vitro protein synthesis |
| DE10336705A1 (de) * | 2003-08-06 | 2005-03-10 | Rina Netzwerk Rna Technologien | Verfahren zur Herstellung eines Lysats zur zellfreien Proteinbiosynthese |
| ES2398463T3 (es) | 2003-09-30 | 2013-03-19 | Daiichi Sankyo Company, Limited | Método de escisión de polipéptidos usando un mutante de la proteasa OmpT |
| WO2006082059A1 (en) * | 2005-02-02 | 2006-08-10 | Universität Bayreuth | Esterases for monitoring protein biosynthesis in vitro |
| CN104789536A (zh) | 2005-10-12 | 2015-07-22 | 斯克利普斯研究院 | 噬菌体展示多肽的选择性翻译后修饰 |
| WO2007109035A2 (en) * | 2006-03-16 | 2007-09-27 | The Scripps Research Institute | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine |
| EP2379578A4 (en) | 2009-01-12 | 2012-05-02 | Sutro Biopharma Inc | DOUBLE-LOADING SYSTEM FOR THE SELECTIVE INTRODUCTION OF NON-NITIVE AMINO ACIDS IN PROTEINS DUE TO AN IN VITRO-SYNTHESIS PROCESS |
| SG11201502875VA (en) * | 2012-10-12 | 2015-06-29 | Sutro Biopharma Inc | Proteolytic inactivation of select proteins in bacterial extracts for improved expression |
-
2013
- 2013-10-08 SG SG11201502875VA patent/SG11201502875VA/en unknown
- 2013-10-08 CA CA2887355A patent/CA2887355C/en active Active
- 2013-10-08 WO PCT/US2013/063804 patent/WO2014058830A1/en not_active Ceased
- 2013-10-08 KR KR1020157012291A patent/KR102018863B1/ko active Active
- 2013-10-08 CN CN201380063443.9A patent/CN104837863B/zh active Active
- 2013-10-08 HU HUE13779699A patent/HUE041721T2/hu unknown
- 2013-10-08 AU AU2013329464A patent/AU2013329464C1/en active Active
- 2013-10-08 JP JP2015536826A patent/JP6421122B2/ja active Active
- 2013-10-08 EP EP13779699.1A patent/EP2906592B1/en active Active
- 2013-10-08 DK DK13779699.1T patent/DK2906592T3/en active
- 2013-10-08 ES ES13779699.1T patent/ES2694683T3/es active Active
- 2013-10-08 PL PL13779699T patent/PL2906592T3/pl unknown
- 2013-10-08 US US14/434,391 patent/US9650621B2/en active Active
-
2015
- 2015-04-01 IL IL23809515A patent/IL238095B/en active IP Right Grant
-
2017
- 2017-04-10 US US15/483,766 patent/US10450353B2/en active Active
- 2017-11-29 JP JP2017229231A patent/JP2018029621A/ja not_active Withdrawn
-
2019
- 2019-09-06 US US16/562,837 patent/US11261219B2/en active Active
-
2020
- 2020-10-14 JP JP2020173282A patent/JP2021003134A/ja not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| Okuno K. et al. "Utilization of Escherichia coli Outer-Membrane Endoprotease OmpT Variants as Processing Enzymes for Production of Peptides from Designer Fusion Proteins" APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2004) 70(1): 76–86 * |
Also Published As
| Publication number | Publication date |
|---|---|
| PL2906592T3 (pl) | 2019-07-31 |
| JP2018029621A (ja) | 2018-03-01 |
| ES2694683T3 (es) | 2018-12-26 |
| AU2013329464A1 (en) | 2015-05-14 |
| US20170283469A1 (en) | 2017-10-05 |
| SG11201502875VA (en) | 2015-06-29 |
| HUE041721T2 (hu) | 2019-05-28 |
| KR102018863B1 (ko) | 2019-09-05 |
| US11261219B2 (en) | 2022-03-01 |
| DK2906592T3 (en) | 2018-12-10 |
| CA2887355A1 (en) | 2014-04-17 |
| US20200062807A1 (en) | 2020-02-27 |
| KR20150064209A (ko) | 2015-06-10 |
| IL238095A0 (en) | 2015-05-31 |
| CN104837863B (zh) | 2018-06-19 |
| CN104837863A (zh) | 2015-08-12 |
| JP2021003134A (ja) | 2021-01-14 |
| EP2906592B1 (en) | 2018-10-03 |
| JP2015531407A (ja) | 2015-11-02 |
| AU2013329464B2 (en) | 2017-07-27 |
| WO2014058830A1 (en) | 2014-04-17 |
| US20150259664A1 (en) | 2015-09-17 |
| US10450353B2 (en) | 2019-10-22 |
| US9650621B2 (en) | 2017-05-16 |
| IL238095B (en) | 2019-11-28 |
| CA2887355C (en) | 2023-03-07 |
| EP2906592A1 (en) | 2015-08-19 |
| JP6421122B2 (ja) | 2018-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013329464C1 (en) | Proteolytic inactivation of select proteins in bacterial extracts for improved expression | |
| EP2376647B1 (en) | Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system | |
| Rother et al. | Identification and characterisation of the selenocysteine-specific translation factor SelB from the archaeon Methanococcus jannaschii | |
| CN107614689A (zh) | 用于将非天然氨基酸并入蛋白质中的平台 | |
| WO2014194129A2 (en) | Cell-free synthetic incorporation of non-natural amino acids into proteins | |
| KR20170074120A (ko) | 과당으로부터 알로오스를 생산하는 균주 및 이를 이용한 알로오스 생산방법 | |
| JP4936290B2 (ja) | 非天然型アミノ酸を組み込んだタンパク質の製造方法 | |
| JPWO2020067550A1 (ja) | 化合物ライブラリー及び化合物ライブラリーの製造方法 | |
| CN107109446A (zh) | 顺式‑5‑羟基‑l‑哌可酸的制造方法 | |
| KR101219716B1 (ko) | 제한효소의 생산방법 | |
| JP6804467B2 (ja) | 組換え型ヌクレオシド特異的リボヌクレアーゼ及びその生成法と使用法 | |
| Novikov et al. | The highly efficient expression of the aspartase gene (L-aspartate ammonia-lyase) in Escherichia coli cells | |
| JP2019170225A (ja) | エンドリボヌクレアーゼ、およびその阻害物質 | |
| HK1167003A (en) | Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 NOV 2017 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 NOV 2017 |
|
| FGA | Letters patent sealed or granted (standard patent) |